Literature DB >> 27157848

A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.

Belinda Gray1, Richard D Bagnall2, Lien Lam2, Jodie Ingles1, Christian Turner3, Eric Haan4, Andrew Davis5, Pei-Chi Yang6, Colleen E Clancy6, Raymond W Sy7, Christopher Semsarian8.   

Abstract

BACKGROUND: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a lethal inherited arrhythmia syndrome characterized by adrenergically stimulated ventricular tachycardia. Mutations in the cardiac ryanodine receptor gene (RYR2) cause an autosomal dominant form of CPVT, while mutations in the cardiac calsequestrin 2 gene (CASQ2) cause an autosomal recessive form.
OBJECTIVE: The aim of this study was to clinically and genetically evaluate a large family with severe autosomal dominant CPVT.
METHODS: Clinical evaluation of family members was performed, including detailed history, physical examination, electrocardiogram, exercise stress test, and autopsy review of decedents. We performed genome-wide linkage analysis in 12 family members and exome sequencing in 2 affected family members. In silico models of mouse and rabbit myocyte electrophysiology were used to predict potential disease mechanisms.
RESULTS: Severe CPVT with dominant inheritance in 6 members was diagnosed in a large family with 2 sudden deaths, 2 resuscitated cardiac arrests, and multiple appropriate implantable cardioverter-defibrillator shocks. A comprehensive analysis of cardiac arrhythmia genes did not reveal a pathogenic variant. Exome sequencing identified a novel heterozygous missense variant in CASQ2 (Lys180Arg) affecting a highly conserved residue, which cosegregated with disease and was absent in unaffected family members. Genome-wide linkage analysis confirmed a single linkage peak at the CASQ2 locus (logarithm of odds ratio score 3.01; θ = 0). Computer simulations predicted that haploinsufficiency was unlikely to cause the severe CPVT phenotype and suggested a dominant negative mechanism.
CONCLUSION: We show for the first time that a variant in CASQ2 causes autosomal dominant CPVT. Genetic testing in dominant CPVT should include screening for heterozygous CASQ2 variants.
Copyright © 2016 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autosomal dominant; CPVT; Cardiac calsequestrin; Heterozygous

Mesh:

Substances:

Year:  2016        PMID: 27157848      PMCID: PMC5453511          DOI: 10.1016/j.hrthm.2016.05.004

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  32 in total

Review 1.  HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.

Authors:  Silvia G Priori; Arthur A Wilde; Minoru Horie; Yongkeun Cho; Elijah R Behr; Charles Berul; Nico Blom; Josep Brugada; Chern-En Chiang; Heikki Huikuri; Prince Kannankeril; Andrew Krahn; Antoine Leenhardt; Arthur Moss; Peter J Schwartz; Wataru Shimizu; Gordon Tomaselli; Cynthia Tracy
Journal:  Heart Rhythm       Date:  2013-08-30       Impact factor: 6.343

Review 2.  Catecholaminergic polymorphic ventricular tachycardia.

Authors:  Antoine Leenhardt; Isabelle Denjoy; Pascale Guicheney
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-09-27

3.  The assembly of calcium release units in cardiac muscle.

Authors:  Clara Franzini-Armstrong; Feliciano Protasi; Pierre Tijskens
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

4.  Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia.

Authors:  Alex V Postma; Isabelle Denjoy; Theo M Hoorntje; Jean-Marc Lupoglazoff; Antoine Da Costa; Pascale Sebillon; Marcel M A M Mannens; Arthur A M Wilde; Pascale Guicheney
Journal:  Circ Res       Date:  2002-10-18       Impact factor: 17.367

Review 5.  Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis.

Authors:  Silvia G Priori; S R Wayne Chen
Journal:  Circ Res       Date:  2011-04-01       Impact factor: 17.367

6.  Functional effects of mutations in KvLQT1 that cause long QT syndrome.

Authors:  Z Wang; M Tristani-Firouzi; Q Xu; M Lin; M T Keating; M C Sanguinetti
Journal:  J Cardiovasc Electrophysiol       Date:  1999-06

7.  The dominant negative LQT2 mutation A561V reduces wild-type HERG expression.

Authors:  A Kagan; Z Yu; G I Fishman; T V McDonald
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

8.  A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel.

Authors:  H Lahat; E Pras; T Olender; N Avidan; E Ben-Asher; O Man; E Levy-Nissenbaum; A Khoury; A Lorber; B Goldman; D Lancet; M Eldar
Journal:  Am J Hum Genet       Date:  2001-10-25       Impact factor: 11.025

9.  SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information.

Authors:  Marco Biasini; Stefan Bienert; Andrew Waterhouse; Konstantin Arnold; Gabriel Studer; Tobias Schmidt; Florian Kiefer; Tiziano Gallo Cassarino; Martino Bertoni; Lorenza Bordoli; Torsten Schwede
Journal:  Nucleic Acids Res       Date:  2014-04-29       Impact factor: 16.971

10.  In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Pei-Chi Yang; Jonathan D Moreno; Christina Y Miyake; Steven B Vaughn-Behrens; Mao-Tsuen Jeng; Eleonora Grandi; Xander H T Wehrens; Sergei Y Noskov; Colleen E Clancy
Journal:  J Physiol       Date:  2015-12-30       Impact factor: 5.182

View more
  21 in total

1.  Gene therapy for inherited arrhythmias.

Authors:  Vassilios J Bezzerides; Maksymilian Prondzynski; Lucie Carrier; William T Pu
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

2.  The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry.

Authors:  Thomas M Roston; Zhiguang Yuchi; Prince J Kannankeril; Julie Hathaway; Jeffrey M Vinocur; Susan P Etheridge; James E Potts; Kathleen R Maginot; Jack C Salerno; Mitchell I Cohen; Robert M Hamilton; Andreas Pflaumer; Saira Mohammed; Lynn Kimlicka; Ronald J Kanter; Martin J LaPage; Kathryn K Collins; Roman A Gebauer; Joel D Temple; Anjan S Batra; Christopher Erickson; Maria Miszczak-Knecht; Peter Kubuš; Yaniv Bar-Cohen; Michal Kantoch; Vincent C Thomas; Gabriele Hessling; Chris Anderson; Ming-Lon Young; Sally H J Choi; Michel Cabrera Ortega; Yung R Lau; Christopher L Johnsrude; Anne Fournier; Filip Van Petegem; Shubhayan Sanatani
Journal:  Europace       Date:  2018-03-01       Impact factor: 5.214

Review 3.  Calcium Signaling and Cardiac Arrhythmias.

Authors:  Andrew P Landstrom; Dobromir Dobrev; Xander H T Wehrens
Journal:  Circ Res       Date:  2017-06-09       Impact factor: 17.367

Review 4.  The function and regulation of calsequestrin-2: implications in calcium-mediated arrhythmias.

Authors:  Elliot T Sibbles; Helen M M Waddell; Valeria Mereacre; Peter P Jones; Michelle L Munro
Journal:  Biophys Rev       Date:  2022-01-07

5.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.

Authors:  Arthur A M Wilde; Christopher Semsarian; Manlio F Márquez; Alireza Sepehri Shamloo; Michael J Ackerman; Euan A Ashley; Back Sternick Eduardo; Héctor Barajas-Martinez; Elijah R Behr; Connie R Bezzina; Jeroen Breckpot; Philippe Charron; Priya Chockalingam; Lia Crotti; Michael H Gollob; Steven Lubitz; Naomasa Makita; Seiko Ohno; Martín Ortiz-Genga; Luciana Sacilotto; Eric Schulze-Bahr; Wataru Shimizu; Nona Sotoodehnia; Rafik Tadros; James S Ware; David S Winlaw; Elizabeth S Kaufman; Takeshi Aiba; Andreas Bollmann; Jong-Il Choi; Aarti Dalal; Francisco Darrieux; John Giudicessi; Mariana Guerchicoff; Kui Hong; Andrew D Krahn; Ciorsti Mac Intyre; Judith A Mackall; Lluís Mont; Carlo Napolitano; Pablo Ochoa Juan; Petr Peichl; Alexandre C Pereira; Peter J Schwartz; Jon Skinner; Christoph Stellbrink; Jacob Tfelt-Hansen; Thomas Deneke
Journal:  J Arrhythm       Date:  2022-05-31

Review 6.  Role of Ca2+ in healthy and pathologic cardiac function: from normal excitation-contraction coupling to mutations that cause inherited arrhythmia.

Authors:  Joshua A Keefe; Oliver M Moore; Kevin S Ho; Xander H T Wehrens
Journal:  Arch Toxicol       Date:  2022-10-10       Impact factor: 6.168

Review 7.  Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.

Authors:  Matthew J Wleklinski; Prince J Kannankeril; Bjӧrn C Knollmann
Journal:  J Physiol       Date:  2020-04-27       Impact factor: 5.182

8.  Genomic-based diagnosis of arrhythmia disease in a personalized medicine era.

Authors:  Abdullah Omar; Mi Zhou; Adam Berman; Robert A Sorrentino; Neela Yar; Neal L Weintraub; Il-Man Kim; Wei Lei; Yaoliang Tang
Journal:  Expert Rev Precis Med Drug Dev       Date:  2016-12-02

9.  Life-threatening arrhythmias with autosomal recessive TECRL variants.

Authors:  Gregory Webster; Elhadi H Aburawi; Marie A Chaix; Stephanie Chandler; Roger Foo; A K M Monwarul Islam; Janneke A E Kammeraad; John D Rioux; Lihadh Al-Gazali; Md Zahidus Sayeed; Tingting Xiao; Han Zhang; Lijian Xie; Cuilan Hou; Alexander Ing; Kai Lee Yap; Arthur A M Wilde; Zahurul A Bhuiyan
Journal:  Europace       Date:  2021-05-21       Impact factor: 5.214

Review 10.  Calsequestrin, a key protein in striated muscle health and disease.

Authors:  Daniela Rossi; Alessandra Gamberucci; Enrico Pierantozzi; Caterina Amato; Loredana Migliore; Vincenzo Sorrentino
Journal:  J Muscle Res Cell Motil       Date:  2020-06-02       Impact factor: 2.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.